Mechanism

TrialResults-center.org

Menu

Phosphoinositide 3-kinase inhibitor

Taselisib

advanced breast cancer (metastatic), in all type of patients

vs fulvestrant alone

Endpoint	TE [95% CI]	p val	I2	n	k

Trial	Studied treatment	Control	Patients
SANDPIPER, 2018	taselisib (4 mg oral, qd) FULV (500 mg)	palcebo FULV (500 mg)	postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative, PIK3CA-mutant, unresectable, locally advanced or metastatic breast cancer after recurrence or progression during or after an aromatase inhibitor (AI) therapy

Modal title

- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy -